CONCLUSION: The majority of patients with HER-2/neu–overexpressing cancers can develop immunity to both HER-2/neu peptides and protein. In addition, the generation of protein-specific immunity, after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback